Revakinagene taroretcel
As of the edition of 20 October 2026, Revakinagene taroretcel is a gene: marketed, first approved in 2025 (US); US protection ends in 2037.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Gene
- Brand name
- encelto
- First approved
- 5 March 2025 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Neurotech Pharmaceuticals
US protection
US protection ends in 2037.
The reference-product exclusivity ends in 2037. The application that gives this date is held by Neurotech Pharmaceuticals.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Neurotech Pharmaceuticals | Originator | 2025 to now |